Page 13 - Patrick Barth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

F. Hoffmann-La Roche Ltd Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years The European Commission (EC) has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above The EC has also approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above Xofluz...

(2) uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis aid pathologists in providing faster, more accurate patient diagnoses in breast cancer In combination with the VENTANA DP 200 slide scanner and Roche uPath enterprise software, the new algorithms provide innovative digital pathology solutions to advance personalised healthcare Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year. About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD laun...

(2) The European Commission (EC) has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above The EC has also approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above Xofluza, with its rapid reduction in viral replication, could help patients recover more quickly, while also reducing the societal burden of influenza Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has approved Xofluza (baloxavir marboxil) for the treatment of uncompl...

Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis aid pathologists in providing faster, more accurate patient diagnoses in breast cancer In combination with the VENTANA DP 200 slide scanner and Roche uPath enterprise software, the new algorithms provide innovative digital pathology solutions to advance personalised healthcare  Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year. About 15 to 20 percent of women diagnosed with breast cance...

F. Hoffmann-La Roche Ltd: European Commission approves Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer 1,2,3 administered under the skin in just minutes compared to hours with intravenous ( IV) infusion of Perjeta plus Herceptin 4,5,6 Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered non-inferior 7 Basel, 23 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo , a fixed-dose combination...